The latest news about Lumendi
LUMENDI RECEIVES CE MARK FOR DILUMEN™ EZ¹ AND DILUMEN™ C¹, EXPANDING FOOTPRINT IN THE EUROPEAN MARKET
This certification is a key milestone in our global strategy to expand access to minimally invasive endoluminal procedures
Lumendi Continues Training Future GI Leaders Through Long-Standing Industry Collaboration
Lumendi Supports Advanced Gastroenterology Training at the Florida Third Space Endoscopy Workshop
Lumendi sponsored the Florida Third Space Endoscopy Workshop from November 17-19, 2024, at the AdventHealth Nicholson Center, emphasizing its commitment to advancing gastroenterology training. Participants had the opportunity to enhance their skills in Endoscopic Submucosal Dissection (ESD) techniques through hands-on sessions with Lumendi’s innovative interventional platforms.
Demonstrating Significant Time and Cost Savings in Colorectal ESD
The prospective, randomized controlled study found that DiLumen reduced total procedure time by 36.5%, leading to an average cost savings of $610.16 per patient.
EZ¹ successfully completes Customer Evaluation phase.
Lumendi receives 510k clearance for two new devices
A successful Digestive Disease Week (DDW) conference in San Diego
Since the company’s inception, we have accumulated over 100 DiLumen users worldwide. Half of these physicians have begun using our devices in the last 12 to 18 months. This year’s DDW was our first opportunity in three years to present Lumendi and our significantly enhanced DiLumen platform to users and industry.
Company Achieves New Milestone with 3,000 Therapeutic Procedures Completed Across U.S., Europe, and Asia Using DiLumen™ EIP
Lumendi Reports Successful Completion Of Dilumen™ Eip First-in-human Trials
30% of surgical interventions are unnesessary
Introducing EZ Glide in Europe
Many studies have documented that an endoscopic approach for ESD is a safer and less expensive alternative to removing these polyps, leading to fewer postoperative complications and shorter hospital stays.